RLTBIO synthesis of cyclo-dodecapeptides with ornithine substitution and triazole stabilization for enhanced stability, cell migration, and hyaluronic acid transdermal delivery in cosmetic dermatology
Journal of Dermatologic Science and Cosmetic Technology · 2026-08 · 100183
DOI: 10.1016/j.jdsct.2026.100183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Dermatologic Science and Cosmetic Technology, 2026-08. Verfasst von Kai Guo und 2 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Shandong Province.
Abstract (Originalsprache)
Purpose
This study investigates the synthetic cyclo-dodecapeptide RCP1203, characterized by a disulfide bond formed from natural amino acids, and assesses the effects of structural modifications on its biological activity. First, two variants of the parent cyclo-dodecapeptide RCP1203 were designed: RCP1209, with lysine replaced by ornithine, and RCP1206, in which a disulfide bond is replaced by a 1,2,3-triazole linkage to enhance stability and bioactivity. Additionally, the study compares the yield, purity, and material efficiency of triazole-mediated peptide synthesis with traditional solid-phase synthesis methods.
Methods
The biological activities of RCP1203, RCP1209, and RCP1206 were evaluated through in vitro assays, including MTT assays for cytotoxicity and cell proliferation, plasma stability tests, scratch assays for cell migration, and hyaluronic acid (HA) transdermal absorption studies. RCP1206 was synthesized using both triazole-mediated peptide synthesis and traditional solid-phase methods, integrating non-natural amino acids and triazole stabilization.
Results
All peptides demonstrated low cytotoxicity. RCP1209 and RCP1206 exhibited superior plasma stability (>74% compared with 65% at 48 h), enhanced HaCaT and HUVEC proliferation (126%/128% compared with 123% for HaCaT; 120%/122% compared with 117% for HUVEC at 50 µg/mL), and promoted wound healing, with RCP1206 showing the highest efficacy. RCP1206 also achieved the greatest transdermal enhancement (3.71-fold). RLTBIO Synthesis doubled yields and halved Fmoc-amino acid consumption.
Conclusion
The biological activities of RCP1203, RCP1209, and RCP1206 were evaluated. These in vitro findings suggest their potential for use in cosmetic formulations. These peptides show potential as ingredients for anti-aging and skin-repair formulations, and may be particularly suitable for use in products designed for sensitive skin. Ornithine substitution and triazole linkage enhance plasma stability, promote cell proliferation, and improve hyaluronic acid (HA) delivery efficiency. triazole-mediated peptide synthesis provides a sustainable, PFAS-free platform for green synthesis of diverse functional peptides, advancing the cosmetics industry’s PFAS replacement initiative.
Förderung
- Department of Science and Technology of Shandong Province
Zitieren
APA
Guo, K., Ji, S., & Zhao, Y. (2026). RLTBIO synthesis of cyclo-dodecapeptides with ornithine substitution and triazole stabilization for enhanced stability, cell migration, and hyaluronic acid transdermal delivery in cosmetic dermatology. Journal of Dermatologic Science and Cosmetic Technology, 100183. https://doi.org/10.1016/j.jdsct.2026.100183
Vancouver
Guo K, Ji S, Zhao Y. RLTBIO synthesis of cyclo-dodecapeptides with ornithine substitution and triazole stabilization for enhanced stability, cell migration, and hyaluronic acid transdermal delivery in cosmetic dermatology. Journal of Dermatologic Science and Cosmetic Technology. 2026:100183. doi:10.1016/j.jdsct.2026.100183
BibTeX
@article{Guo2026,
author = {Guo, Kai and Ji, Shengli and Zhao, Yuetong},
title = {RLTBIO synthesis of cyclo-dodecapeptides with ornithine substitution and triazole stabilization for enhanced stability, cell migration, and hyaluronic acid transdermal delivery in cosmetic dermatology},
journal = {Journal of Dermatologic Science and Cosmetic Technology},
year = {2026},
pages = {100183},
doi = {10.1016/j.jdsct.2026.100183}
}
EUVIMED